NEW YORK--(BUSINESS WIRE)--Sep. 30, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in October:
2019 Cantor Global Healthcare Conference
- Wednesday, October 2nd
- 8:20AM Eastern Time
- New York, NY
A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available on the website for approximately two weeks.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190930005209/en/
Source: UroGen Pharma Ltd.
Senior Director, Investor Relations